Kineta, Inc. KA
At closeSep 18, 2024, 4:00 PM EDT
- YTD
- 0.00%
- 1 year
- 0.00%
- Market cap
- 7.05M
- EPS (ttm)
- -1.64
- Shares out
- 12.26M
- P/E ratio
- -0.35
- Forward P/E
- -0.43
- YTD return
- 0.00%
- 1-year return
- 0.00%
- Volume
- 480.68K
- Avg volume
- 504.10K
- Open
- 0.7801
- Previous close
- 0.5746
- Day's range
- 0.56 – 0.825
- 52-week range
- 0.3339 – 5.39
- Analysts
- Buy
- Price target
- 13.50 (+2249.5%)
- Earnings date
- Nov 1, 2024
Key statistics
- Enterprise value
- 8.55M
- PEG ratio
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -3.17M
- Total cash
- 900.00K
- Total debt
- 710.00K
- Return on equity
- 0.00%
- Short % of float
- 0.31%
- 50-day average
- 0.649607
- 200-day average
- 1.12
Analyst view
Consensus: buy
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 1, 2024
Expected Nov 1, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 1, 2024 | Sep 1, 2024 | 0.00 | — | — | — |
| Aug 8, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| May 15, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| Mar 21, 2024 | Dec 1, 2023 | -0.29 | — | — | — |
| Nov 3, 2023 | Sep 1, 2023 | -0.55 | — | — | — |
| Aug 11, 2023 | Jun 1, 2023 | -0.62 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 20, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| May 17, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Apr 30, 2023 | HC Wainwright & Co. | init | — | Buy |
About Kineta, Inc.
Kineta, Inc. is a clinical-stage biotechnology company with a focus on developing immunotherapies that transform patients' lives. It focuses on developing potentially differentiated immunotherapies that address the challenges with current cancer therapy. The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (mAb) infusion drug. KVA12123 is being evaluated in a Phase 1/2 clinical trial as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors, including non-small cell lung, ovarian, renal cell carcinoma, head and neck, renal cell, and colorectal cancers. It is also developing anti-CD27 agonist mAb immunotherapy to address the problem of exhausted T cells. The company has collaboration and license agreements with MSD International Business GmbH, Genentech, Inc., FAIR Therapeutics B.V., and GigaGen, Inc. Kineta, Inc. is headquartered in Seattle, Washington.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- kinetabio.com
News
12 Health Care Stocks Moving In Thursday's After-Market Session 
12 Health Care Stocks Moving In Friday's After-Market Session 
12 Health Care Stocks Moving In Thursday's Intraday Session 
12 Health Care Stocks Moving In Wednesday's Intraday Session 
Why Ascent Solar Technologies Shares Are Trading Lower By Around 50%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session 
Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session - 12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Thursday's After-Market Session 
Why SOPHiA GENETICS Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session - Why Bitdeer Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Your note
Sign in to keep a note on KA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAKER KEITH | Chief Financial Officer | Purchase | Sep 17, 2023 | 16,880 |
| BARTOSZEK RAYMOND JOSEPH | Director | Purchase | Dec 5, 2023 | 863,685 |
| FOOTE MARION R | Director | Conversion of Exercise of derivative security | Oct 10, 2023 | 143,204 |
| GUILLAUDEUX THIERRY | Officer | Purchase | Sep 13, 2023 | 21,696 |
| IADONATO SHAWN P | Chief Executive Officer | Purchase | Nov 28, 2023 | 683,783 |
| KENNY PAULINE | General Counsel | Purchase | Sep 19, 2023 | 18,448 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Armistice Capital, LLC | 8.97% | 876,000 | 2.26M | Jun 29, 2023 |
| Colony Group LLC | 1.42% | 139,201 | 359.14K | Jun 29, 2023 |
| FMR, LLC | 1.27% | 123,719 | 319.19K | Jun 29, 2023 |
| Vanguard Group Inc | 0.63% | 61,561 | 158.83K | Jun 29, 2023 |
| Artal Group S.A. | 0.32% | 31,055 | 80.12K | Jun 29, 2023 |
| Renaissance Technologies, LLC | 0.28% | 26,916 | 69.44K | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 0.34% | 32,976 | 85.08K | Jun 29, 2023 |
| Fidelity Growth Company Fund | 0.31% | 30,558 | 60.81K | Aug 30, 2023 |
| Vanguard Extended Market Index Fund | 0.29% | 28,255 | 72.90K | Jun 29, 2023 |
| iShares Micro Cap ETF | 0.13% | 12,978 | 25.83K | Aug 30, 2023 |
| Schwab Capital Trust-Total Stock Market Index Fund | 0.08% | 8,000 | 16.88K | Jul 30, 2023 |
| Fidelity Growth Company K6 Fund | 0.05% | 5,211 | 15.69K | May 30, 2023 |